Should I buy or sell GH Research stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GH Research in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GHRS shares. View GHRS analyst ratings or view top-rated stocks .

What is GH Research's stock price target for 2024?

2 equities research analysts have issued 1 year price objectives for GH Research's stock. Their GHRS share price targets range from $39.00 to $40.00. On average, they predict the company's share price to reach $39.50 in the next twelve months. This suggests a possible upside of 259.4% from the stock's current price. View analysts price targets for GHRS or view top-rated stocks among Wall Street analysts .

How have GHRS shares performed in 2024?

GH Research's stock was trading at $5.80 on January 1st, 2024. Since then, GHRS shares have increased by 89.5% and is now trading at $10.99. View the best growth stocks for 2024 here .

When is GH Research's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our GHRS earnings forecast .

How were GH Research's earnings last quarter?

GH Research PLC (NASDAQ:GHRS) released its quarterly earnings data on Thursday, February, 29th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by $0.01.

What ETFs hold GH Research's stock?

ETFs with the largest weight of GH Research (NASDAQ:GHRS) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL) . iShares MSCI Ireland ETF (EIRL) .

When did GH Research IPO?

GH Research (GHRS) raised $150 million in an initial public offering on Friday, June 25th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share.

How do I buy shares of GH Research?

Shares of GHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:GHRS

GH Research (GHRS) Stock Price, News & Analysis

→ Can't believe it's happening again (From Manward Press) (Ad)

Free GHRS Stock Alerts

$10.99

-0.73 (-6.23%)

(As of 05:12 PM ET)

Compare

Today's Range: $10.94
▼
$11.92
50-Day Range: $7.44
▼
$11.72
52-Week Range: $5.05
▼
$14.64

Volume: 36,555 shs
Average Volume: 136,669 shs
Market Capitalization: $571.81 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $39.50

Get GH Research alerts:

GH Research MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 259.4% Upside
$39.50 Price Target
Short Interest: Bearish
4.47% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.63
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.96) to ($1.17) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.15 out of 5 stars

Medical Sector

762nd out of 930 stocks

Pharmaceutical Preparations Industry

341st out of 420 stocks

3.5

Analyst's Opinion

Consensus Rating
GH Research has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
GH Research has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
4.47% of the float of GH Research has been sold short.
Short Interest Ratio / Days to Cover
GH Research has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.
Change versus previous month

0.0

Dividend Strength

Dividend Yield
GH Research does not currently pay a dividend.
Dividend Growth
GH Research does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GHRS.

3.1

News and Social Media Coverage

News Sentiment
GH Research has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for GH Research this week, compared to 1 article on an average week.
Search Interest
4 people have searched for GHRS on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.
MarketBeat Follows
3 people have added GH Research to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, GH Research insiders have not sold or bought any company stock.
Percentage Held by Institutions
56.90% of the stock of GH Research is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for GH Research are expected to decrease in the coming year, from ($0.96) to ($1.17) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of GH Research is -16.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of GH Research is -16.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
GH Research has a P/B Ratio of 2.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Manward Press

Can't believe it's happening again

One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.

We explain how this event works in full right here.

About GH Research Stock (NASDAQ:GHRS)

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies to treat psychiatric and neurological disorders. The company develops 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable mebufotenin product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an intravenous mebufotenin product candidate; and GH003, an intranasal mebufotenin product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.

GHRS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GHRS Stock News Headlines

April 12, 2024 | americanbankingnews.com

GH Research (NASDAQ:GHRS) Trading Down 0.5%

March 17, 2024 | yahoo.com

General Hospital Video Preview: Misdirections, Maladies, and Misdiagnoses

April 16, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 15, 2024 | yahoo.com

General Hospital Video Preview: Catastrophic Thoughts Plague Jason and Sonny

March 15, 2024 | yahoo.com

The General Hospital Coming Out Storyline Nobody Saw Coming

March 4, 2024 | markets.businessinsider.com

Buy Rating for GH Research: Promising Clinical Trials and Strategic Intellectual Property Advances

March 1, 2024 | markets.businessinsider.com

Buy Rating Justified by GH Research’s Promising Clinical Trials and Strong Financial Health

March 1, 2024 | msn.com

GH Research: This European Biotech Company Reports Full Year 2023 Financial Results And Business Updates

April 16, 2024 | Manward Press (Ad)

Can't believe it's happening again

February 29, 2024 | globenewswire.com

GH Research Reports Full Year 2023 Financial Results and Provides Business Updates

January 18, 2024 | finance.yahoo.com

GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression

January 16, 2024 | finance.yahoo.com

Can GH Research PLC (GHRS) Climb 488.72% to Reach the Level Wall Street Analysts Expect?

January 16, 2024 | yahoo.com

General Hospital Season 61: How Many Episodes & When Do New Episodes Come Out?

December 26, 2023 | yahoo.com

General Hospital Season 61 Streaming: Watch & Stream Online via Hulu

December 25, 2023 | finance.yahoo.com

We're Hopeful That GH Research (NASDAQ:GHRS) Will Use Its Cash Wisely

December 20, 2023 | nasdaq.com

These Four Stocks Tap into the Exploding Psychedelic Treatment Market

November 24, 2023 | msn.com

Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More

November 11, 2023 | markets.businessinsider.com

Analysts Offer Insights on Technology Companies: Inuvo (INUV) and GH Research (GHRS)

November 10, 2023 | markets.businessinsider.com

GH Research Earns ‘Buy’ Rating: Promising Progress, Proactive Approach, and Solid Financial Standing

November 10, 2023 | finanznachrichten.de

GH Research PLC: GH Research Reports Third Quarter Financial Results and Provides Business Updates

November 9, 2023 | finance.yahoo.com

GH Research Reports Third Quarter Financial Results and Provides Business Updates

November 2, 2023 | morningstar.com

GH Research PLC GHRS

October 3, 2023 | markets.businessinsider.com

Positive Outlook for GH Research Despite FDA’s Clinical Hold: An Analysis of GH001’s Trials and Prospects

October 2, 2023 | benzinga.com

GH Research's Psychedelic Drug Candidate For Depression Meets FDA: Clinical Program On Hold

September 30, 2023 | finanznachrichten.de

GH Research PLC: GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression

September 29, 2023 | finance.yahoo.com

GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression

August 24, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Their Buy Rating for GH Research (GHRS)

See More Headlines

Receive GHRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GH Research and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/29/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:GHRS
CUSIP: N/A
CIK: 1855129
Web: www.ghres.com
Phone: 212-450-4000
Fax: N/A
Employees: 49
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $39.50
High Stock Price Target: $40.00
Low Stock Price Target: $39.00
Potential Upside/Downside: +244.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.68)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-35,590,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -15.48%
Return on Assets: -15.01%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 24.49
Quick Ratio: 24.49

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.94 per share
Price / Book: 2.32

Miscellaneous

Outstanding Shares: 52,030,000
Free Float: N/A
Market Cap: $596.26 million
Optionable: Optionable
Beta: 0.84

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Florian Schonharting M.Sc. (Econ) (Age 55)
Co-Founder & Non-Executive Chairman of the Board
Dr. Theis Terwey M.D. (Age 48)
Co-Founder & CEO
Mr. Magnus Halle (Age 27)
Co-Founder & MD of Ireland
Ms. Julie Ryan F.C.A. (Age 38)
Vice President of Finance
Mr. Aaron Cameron M.B.A. (Age 39)
Chief Operating Officer
Mr. Naoise Gaffney
VP & Head of Intellectual Property
Dr. Velichka Valcheva M.D. (Age 49)
Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

GHRS Stock Analysis - Frequently Asked Questions

Should I buy or sell GH Research stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GH Research in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GHRS shares.
View GHRS analyst ratings or view top-rated stocks.
What is GH Research's stock price target for 2024?: 2 equities research analysts have issued 1 year price objectives for GH Research's stock. Their GHRS share price targets range from $39.00 to $40.00. On average, they predict the company's share price to reach $39.50 in the next twelve months. This suggests a possible upside of 259.4% from the stock's current price.
View analysts price targets for GHRS or view top-rated stocks among Wall Street analysts.
How have GHRS shares performed in 2024?: GH Research's stock was trading at $5.80 on January 1st, 2024. Since then, GHRS shares have increased by 89.5% and is now trading at $10.99.
View the best growth stocks for 2024 here.
When is GH Research's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our GHRS earnings forecast.

How were GH Research's earnings last quarter?: GH Research PLC (NASDAQ:GHRS) released its quarterly earnings data on Thursday, February, 29th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by $0.01.
What ETFs hold GH Research's stock?: ETFs with the largest weight of GH Research (NASDAQ:GHRS) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL).iShares MSCI Ireland ETF (EIRL).
When did GH Research IPO?: GH Research (GHRS) raised $150 million in an initial public offering on Friday, June 25th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share.
How do I buy shares of GH Research?: Shares of GHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GHRS) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial